MRD / Regn No. : THBC\23-24\07137 Date : 23/06/2026
Patient Name : Bharat Shah Age & Gender : 67 Yrs. / Male
Contact No. : 9322220345 UHID :
Ht / Wt / BMI : 165 / 75.95 / 27.90 BP S / BP D : 152 / 81
Allergies : NONE Referred By :
   
Problem List : T2DM (15/Jul/2025) | DYSLIPIDEMIA (15/Jul/2015) |
Subjective : T2DM X 20-25 YRS,HTN X 4-5 YRS,CALF PAIN BETTER,BPH - REDUCED FROM 75 GMS TO 39 GMS,METROPOLIS - 7.3%,GLAUCOMA CHANGES NOTED- VISION NORMAL,SMBG- IN NORMAL RANGE
Objective : 20-JUN-2026 REPORTS,FBS-98.75,HB-14.4/ HBA1C-6.7%,TC-114/ TG-87/ LDL-69/ HDL-35,VITD-52.5,VITB12-993,T3-106/ T4-9.8/ TSH-2.125,CR-1.1,TESTOSTERONE-463,ALT-19.9/ AST-17.9,MAGNESIUM-1.81,LIPASE-39.6,HSCRP-2.4,EGFR-73,AMYLASE-52.3,U ACR-16.6,22-JUN-2026 REPORTS,FBS-103/ PPBS-174
Analysis : OPTIDOZ - TELMISARTAN / HCTZ / AMLODIPINE,VIT D ONCE IN 15 DAYS,NUROKIND LC 2-3 TIMES A WEEK
S# Generic (Trade) Name Route Dosage Usage Duration
1 ZOMELIS SR 100 ORAL 1-0-0 ABF
4 MTHS
2 ROZAT F 10 MG ORAL 0-0-1 AD
4 MTHS
3 OPTIDOZ ORAL 1-0-0 BBF
4 MTHS
4 GEMER 0.5 / GLYCOMET GP 0.5 / GLIMISAVE M 0.5 / ZORYL M 0.5 MG ORAL 1-0-1 BBF / BD
4 MTHS
5 SILODOL D 8 MG ORAL 0-0-1 AD
4 MTHS
6 REFRESH TEARS ORAL 1 DROP BOTH EYES 2-3 TIMES A DAY
12 MTHS
       
Refill : 0 / Substitution:    
Education :
Next Visit : 23/Oct/2026
Tests Suggested For Next Visit : HBA1C REPEAT FROM METROPOLIS AS DISCREPANCY BETWEEN THYROCARE AND METROPOLIS (6.7% VS 7.3%),IF NXT HBA1C ALSO > 7% - CAN CONSIDER OPTIMISING MEDS
   
   

Dr Tejal Lathia
M.D, D.M (Endocrinology)
Maharashtra / 2003/05/2166

This is a Computer generated Prescription

Powered By: